Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Esthesioneuroblastoma, Olfactory × apatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Advanced Non-squamous Non-small-cell Lung Cancer 2 Stomach Neoplasms 1 Sarcoma 1 Lung Neoplasms 1 Esthesioneuroblastoma, Olfactory 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1

Interventions

Docetaxel 2 vandetanib 1 apatinib 1 Therapeutics 1 Hypericum extract LI 160 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06308575 2025-01-10

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn

Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon ⚡